180 Wealth Advisors LLC Sells 35 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

180 Wealth Advisors LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% in the fourth quarter, HoldingsChannel reports. The fund owned 579 shares of the company’s stock after selling 35 shares during the period. 180 Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $239,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. FSA Wealth Management LLC bought a new stake in IDEXX Laboratories during the third quarter worth about $25,000. E Fund Management Hong Kong Co. Ltd. lifted its position in IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the period. Mowery & Schoenfeld Wealth Management LLC lifted its position in IDEXX Laboratories by 750.0% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the period. Strategic Investment Solutions Inc. IL bought a new stake in IDEXX Laboratories during the second quarter worth about $36,000. Finally, Ashton Thomas Securities LLC bought a new stake in IDEXX Laboratories during the third quarter worth about $37,000. Institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IDXX. JPMorgan Chase & Co. cut their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Stifel Nicolaus dropped their target price on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. Piper Sandler reissued a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Two analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $539.63.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $422.92 on Thursday. The business has a 50 day moving average of $423.98 and a 200-day moving average of $458.99. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The company has a market capitalization of $34.63 billion, a P/E ratio of 40.78, a P/E/G ratio of 3.94 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the prior year, the firm posted $2.53 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current year.

Insider Activity

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now owns 905 shares of the company’s stock, valued at approximately $380,498.20. This represents a 27.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.11% of the stock is currently owned by insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.